Augmenting Hit Identification by Virtual Screening Techniques in Small Molecule Drug Discovery.Yan, X.C., Sanders, J.M., Gao, Y.D., Tudor, M., Haidle, A.M., Klein, D.J., Converso, A., Lesburg, C.A., Zang, Y., Wood, H.B.
(2020) J Chem Inf Model 60: 4144-4152
- PubMed: 32309939
- DOI: https://doi.org/10.1021/acs.jcim.0c00113
- Primary Citation of Related Structures:
6VLM, 6VLU, 6VLV
- PubMed Abstract:
Two orthogonal approaches for hit identification in drug discovery are large-scale in vitro and in silico screening. In recent years, due to the emergence of new targets and a rapid increase in the size of the readily synthesizable chemical space, there is a growing emphasis on the integration of the two techniques to improve the hit finding efficiency. Here, we highlight three examples of drug discovery projects at Merck & Co., Inc., Kenilworth, NJ, USA in which different virtual screening (VS) techniques, each specifically tailored to leverage knowledge available for the target, were utilized to augment the selection of high-quality chemical matter for in vitro assays and to enhance the diversity and tractability of hits. Central to success is a fully integrated workflow combining in silico and experimental expertise at every stage of the hit identification process. We advocate that workflows encompassing VS as part of an integrated hit finding plan should be widely adopted to accelerate hit identification and foster cross-functional collaborations in modern drug discovery.